Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

1042689

USP

Aripiprazole Related Compound F

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

7-[4-[4-(2,3-Dichlorophenyl)-1-oxidopiperazin-1-yl]butoxy]-3,4-dihydroquinolein-2(1H)-one, 4-(2,3-Dichlorophenyl)-1-[4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyl]piperazin 1-oxide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H27Cl2N3O3
Numéro CAS:
573691-09-5
Poids moléculaire :
464.38
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

aripiprazole

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C23H27Cl2N3O3/c24-19-4-3-5-21(23(19)25)27-10-13-28(30,14-11-27)12-1-2-15-31-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

Clé InChI

ZNYNDJDSFMRJPS-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Aripiprazole Related Compound F USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0001649

Aripiprazole, European Pharmacopoeia (EP) Reference Standard

Y0001650

Aripiprazole impurity F, European Pharmacopoeia (EP) Reference Standard

1042634

Aripiprazole, United States Pharmacopeia (USP) Reference Standard

1042690

Aripiprazole Related Compound G, United States Pharmacopeia (USP) Reference Standard

1042645

Aripiprazole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1042714

Aripiprazole Related Compound H, United States Pharmacopeia (USP) Reference Standard

PHR1784

Aripiprazole, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2320

Aripiprazole Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2321

1-(2,3-Dichlorophenyl)piperazine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2323

Aripiprazole Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2324

Aripiprazole Related Compound H, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Protocoles

Identification, Assay and Organic Impurity Profiling Methods for Aripiprazole following the United States Pharmacopeia Monograph

Aripiprazole is an atypical antipsychotic and a partial dopamine agonist. It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole was first approved by the U.S. Food and DrugAdministration in November 2002 for schizophrenia and by the European Medicines Agency in June 2004 for acute manic and mixed episodes associated with bipolar disorder.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique